Breaking Down China Animal Husbandry Industry Co., Ltd. Financial Health: Key Insights for Investors

China Animal Husbandry Industry Co., Ltd. (600195.SS) presents a mixed but compelling financial picture that demands a closer look: nine-month sales of CNY 4.44 billion and a TTM revenue of CNY 6.28 billion (up 15.77% year-over-year) sit alongside a nine-month net income jump to CNY 225.36 million (from CNY 81.8 million a year earlier) and a TTM net profit margin of 3.42%; investors should weigh this growth against valuation and cash-flow metrics such as a P/S of 1.31, a TTM EPS of CNY 0.21 with a P/E near 37.15 (and headline TTM P/E of 70.78), total debt of CNY 1.01 billion versus equity of CNY 4.99 billion (D/E ~0.20), and a levered free cash flow of CNY -626.40 million-while liquidity indicators show CNY 621.99 million in cash, a current ratio of 2.22 and a quick ratio of 1.57, operational efficiency metrics reveal an operating margin of 1.62%, ROE of 0.85% and ROA of 0.25%, and valuation gauges (P/B 1.19, EV/EBITDA 24.17) must be judged alongside industry risks like raw-material volatility and regulatory shifts and growth levers including pet-medicine expansion and smart aquaculture exports-read on to parse these figures, their implications for solvency and valuation, and which catalysts could reshape the company's trajectory.

China Animal Husbandry Industry Co., Ltd. (600195.SS) - Revenue Analysis

China Animal Husbandry Industry Co., Ltd. (600195.SS) has shown revenue expansion in recent periods driven by operational scale and improving top-line trends. Key figures highlight momentum through 2024 and into the nine-month period ending September 30, 2025.

• Nine months ended Sep 30, 2025: Sales CNY 4.44 billion, up 6.3% year-over-year.
• TTM revenue as of Sep 30, 2025: CNY 6.28 billion, reflecting 15.77% YoY growth.
• Full-year 2024 revenue: CNY 6.02 billion, an 11.30% increase vs. 2023.
• 10-year average revenue growth: ~3% annually; last 12-month growth: 18%.
• Revenue per employee: ~CNY 1.46 million (4,299 employees).
• Price-to-sales (P/S) ratio: 1.31.

Investor-focused implications and considerations:

• Top-line trajectory: TTM growth (15.77%) and FY2024 growth (11.30%) indicate accelerating revenue versus the longer-term 10-year average (~3%).
• Operational efficiency: Revenue per employee (~CNY 1.46M) provides a productivity benchmark for labor and scaling comparisons with peers.
• Valuation context: A P/S of 1.31 suggests the market is valuing roughly 1.31 times annual sales - useful when comparing industry multiples and growth expectations.
• Seasonality and near-term visibility: Nine-month sales data (CNY 4.44B) should be considered alongside quarter-to-quarter trends to assess end-of-year revenue catch-up or slowdown risk.
• Growth drivers: Recent 18% last-12-month growth implies near-term catalysts-product mix, pricing, volume gains, or M&A-should be reviewed in company disclosures and the linked company background.

Context and further reading: China Animal Husbandry Industry Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

China Animal Husbandry Industry Co., Ltd. (600195.SS) - Profitability Metrics

China Animal Husbandry Industry Co., Ltd. (600195.SS) showed notable profit expansion in the nine months ending September 30, 2025, driven by improved topline and controlled operating costs. Key headline figures and efficiency ratios for the trailing twelve months (TTM) and the nine-month period are highlighted below.

• Nine months ending Sept 30, 2025: Net income CNY 225.36 million (vs. CNY 81.8 million in the same period 2024).
• TTM net income as of Sept 30, 2025: CNY 214.44 million; net profit margin ~3.42%.
• TTM earnings per share (EPS): CNY 0.21; P/E ratio: 37.15.
• TTM operating margin: 1.62%.
• Return on equity (ROE): 0.85%.
• Return on assets (ROA): 0.25%.

Investors seeking deeper context on ownership, recent transactions and who is buying or selling can refer to the related investor profile:

China Animal Husbandry Industry Co., Ltd. (600195.SS) - Debt vs. Equity Structure

• Total debt: CNY 1.01 billion
• Total equity: CNY 4.99 billion
• Debt-to-equity ratio: ~0.20

• Liquidity profile: current ratio 2.22 and quick ratio 1.57 indicate the company can meet near-term obligations without asset sales or additional financing.
• Leverage profile: a debt-to-equity of ~0.20 signals conservative use of debt, lowering financial risk but also suggesting limited tax-shield benefits.
• Profitability vs. interest burden: interest coverage at 0.99 highlights that operating earnings are nearly equal to interest expense, raising concerns if EBITDA falls or interest costs rise.
• Valuation context: EV/EBITDA of 24.17 is elevated, implying market expectations for growth or stability; EV/Revenue of 1.47 shows investors are paying a premium per yuan of sales.

China Animal Husbandry Industry Co., Ltd. (600195.SS) - Liquidity and Solvency

• Cash cushion: CNY 621.99M provides CNY 0.61 per share, a tangible short-term liquidity buffer.
• Operational cash generation: Positive operating cash flow of CNY 71.09M (TTM) shows ongoing cash from core activities.
• Negative levered FCF: Levered free cash flow of CNY -626.40M (TTM) indicates cash shortfall after financing and debt servicing.

• Balance-sheet strength: Book value per share at CNY 5.37 signals meaningful net asset backing for equity holders.
• Debt coverage: Total cash to total debt ≈ 0.62 - the company can cover ~62% of its debt with cash on hand.
• Conservative leverage: Total debt to total assets ≈ 0.17 implies modest leverage and lower balance-sheet risk.

• Implication for investors: positive operating cash flow and low leverage contrast with sizable negative levered FCF, highlighting the importance of monitoring capital expenditures, debt maturities, and financing activities.

China Animal Husbandry Industry Co., Ltd. (600195.SS) - Valuation Analysis

• Trailing twelve months (TTM) P/E: 70.78 - reflects current market price relative to last 12 months' earnings.
• Forward P/E: 30.33 - implies analysts expect material earnings growth versus TTM.
• Price-to-Book (P/B): 1.19 - equity valued modestly above book value.
• Enterprise Value / EBITDA (EV/EBITDA): 24.17 - a relatively elevated multiple indicating price paid for operating cash flow.
• Enterprise Value / Revenue (EV/Revenue): 1.47 - market values each yuan of revenue at ~1.47 yuan of enterprise value.
• PEG: Not available - earnings growth projection for PEG calculation is not provided.

China Animal Husbandry Industry Co., Ltd. (600195.SS) Risk Factors

• Competitive landscape: China Animal Husbandry Industry Co., Ltd. operates in a highly competitive animal health industry with pressure from domestic peers and multinational companies on pricing, distribution, and R&D pipelines. Intense competition can compress margins and limit market share gains.
• Raw material price volatility: Key inputs such as corn and soybean meal are subject to global commodity price swings. Rising raw material costs increase production expense and can materially reduce gross margins if not passed on to customers.
• Regulatory risk: Changes in China's animal health and feed regulations-covering product approvals, veterinary drug residue limits, and biosecurity rules-can delay product launches, restrict market access, or require costly reformulations and compliance investments.
• Leverage and interest burden: The company's debt-to-equity ratio of 0.20 indicates moderate financial leverage, but the interest coverage ratio of 0.99 means operating earnings are just about sufficient to meet interest obligations, raising potential liquidity stress under earnings pressure.
• Negative levered cash flow: Levered free cash flow stands at CNY -626.40 million, indicating that after servicing debt and capital needs the company produced negative cash flow, which could constrain investments in growth, R&D, or working capital during downturns.

• Operational risks: Outbreaks of animal disease, supply chain disruptions, or factory downtime could magnify margin pressure given tight interest coverage.
• Market acceptance and product approvals: New product rollouts depend on regulatory clearances and customer adoption; delays or rejections raise development costs and extend payback periods.
• Refinancing and liquidity risk: With interest coverage near 1.0 and negative levered FCF, the company may face refinancing risk if credit markets tighten or if lenders demand higher spreads.
• Commodity exposure: Prolonged elevated corn/soybean prices or exchange-rate shifts could erode profitability faster than management can adjust pricing.

For context on strategy and long-term priorities, see: Mission Statement, Vision, & Core Values (2026) of China Animal Husbandry Industry Co., Ltd.

China Animal Husbandry Industry Co., Ltd. (600195.SS) - Growth Opportunities

• Pet medications: China's companion animal market reached an estimated RMB 230-260 billion in 2023, with pet healthcare/pharmaceuticals growing at an estimated CAGR of ~12-15% (2020-2024). Entry into pet meds could target a market segment projected to exceed RMB 40-60 billion within five years.
• Overseas expansion: Belt and Road and Shanghai Cooperation Organization (SCO) markets together represent >1.5 billion people with growing protein consumption; regional animal health spend in key B&R countries is estimated at USD 3-6 billion annually. Exporting vaccines, pharmaceuticals and nutrition products can leverage duty-preference corridors and bilateral trade agreements.
• Technology & smart solutions: Demand for intelligent aquaculture and precision livestock equipment is expanding - China's smart agriculture equipment market was ~RMB 80-100 billion in 2023, with related aquaculture/precision farming segments growing >10% YoY. Leveraging exports of smart aquaculture solutions can boost higher-margin sales and service revenues.
• Industry standards & downstream demand: Upgrading biosecurity and meeting tightened regulatory standards (post-ASF and avian influenza responses) increases demand for higher-spec vaccines and prophylactics. Downstream diversification into processed protein and specialty feeds raises overall spend on animal health per unit of livestock production (industry estimates suggest animal health spend per head rising 5-8% annually in mature provinces).
• Strategic Beijing base: Headquarters proximity to central regulators and trade bodies can accelerate clinical trial approvals, policy-awareness and participation in national livestock health initiatives - potentially shortening time-to-market by months versus distant peers.
• Integrated cross-selling: A combined portfolio of vaccines, pharmaceuticals and nutrition enables bundled offerings to large commercial farms and integrated agri-enterprises - farms that adopt integrated health programs can increase per-farm annual procurement by an estimated RMB 0.5-1.5 million for mid-to-large customers.

• Execution considerations for investors: capture pet-med margins by building or partnering for regulatory pathways (CFDA/NMPA approvals), invest in digital and service capabilities to monetize equipment exports, and prioritize markets with compatible regulatory regimes among B&R/SCO members.
• Capital/R&D deployment: targeting a modest reallocation of 1-3% of revenue into pet R&D and 0.5-1% into digital productization could materially shift revenue mix within 3-4 years given current market growth rates.